YU.M. KONOVALOVA, T.M. SUKHOPLYUEVA, T.V. BAIDINA, M.A. DANILOVA

 E.A. Vagner Perm State Medical University, Perm

Contact details:

Danilova M.A. — PhD, Associate Professor of the Department of Neurology and Medical Genetics

Address: 26 Petropavlovskaya St., 614000 Perm, Russian Federation, tel.: +7-902-640-61-72, e-mail: m.a.danilova82@mail.ru

 Cerebral amyloid angiopathy is a phenomenon that pathogenetically combines vascular and neurodegenerative changes in the brain and is characterized by a wide range of clinical and radiological signs. Diagnosis of this pathology is important for assessing the risks of hemorrhagic and ischemic complications, the feasibility of using antithrombotic and anticoagulant drugs, as well as for further prognosis of cognitive impairment. Adequate therapy and correction of cardiovascular risk factors can slow down the disease progression and improve the quality of life of patients and their relatives. The review considers the etiology and pathogenesis of cerebral amyloid angiopathy, its clinical manifestations and phenotypes. The principles of diagnostics including modified Boston criteria as well as up-to-date concepts of the treatment are presented.

Key words: β-amyloid, intracerebral hematomas, cortical superficial siderosis, cognitive impairment, neuroimaging.

REFERENCES

1. Mkhitaryan E.A., Fateeva V.V., Kamchatnov P.R. Cerebral amyloid angiopathy. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova, 2024, vol. 124, no. 2, pp. 1–6(in Russ.).
2. Esin R.G., Khayrullin I.Kh., Abrarova G.F., Esin O.R. Cerebral small vessel disease and asymptomatic cerebrovascular diseases: modern standards of diagnosis, prevention, treatment prospects. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova, 2019, vol. 119, no. 4, pp. 81–87 (in Russ.).
3. Kulesh A.A., Drobakha V.E., Shestakov V.V. Tserebral’naya amiloidnaya angiopatiya: sovremennaya kontseptsiya patogeneza i klinicheskaya znachimost’: uchebnoe posobie [Cerebral amyloid angiopathy: a modern concept of pathogenesis and clinical significance: a tutorial]. Perm: FGBOU VO PGMU im. akad. E.A. Vagnera Minzdrava Rossii, 2019. 80 p.
4. Jäkel L., De Kort A.M., Klijn C.J.M. et al. Prevalence of cerebral amyloid angiopathy: A systematic review and meta-analysis. Alzheimers Dement, 2022, vol. 18 (1), pp. 10–28.
5. Morotti A., Pilotto A., Zanola D. et al. Cerebral amyloid angiopathy in Alzheimer disease. A comparison between different versions of the Boston Criteria. Neurology, 2024, vol. 104 (2), pp. 210–248.
6. Kornilova A.A., Lagoda O.V., Tanashyan M.M. Cerebral amyloid angiopathy in combination with paroxysmal atrial fibrillation. Rossiyskiy nevrologicheskiy zhurnal, 2020, vol. 25, no. 4, pp. 31–37 (in Russ.).
7. Banerjee G., Collinge J., Fox N.C. et al. Clinical considerations in early-onset cerebral amyloid angiopathy. Brain, 2023, vol. 146 (10, pp. 3991–4014.
8. Novosadova O.A., Kulesh A.A., Grigor’eva V.N. Diagnostics of cerebral amyloid angiopathy: towards the Boston criteria 2.0. Rossiyskiy nevrologicheskiy zhurnal, 2020, vol. 25, no. 5, pp. 4–13 (in Russ.).
9. Kozberg M.G., van Veluw S.J., Frosch M.P., Greenberg S.M. Hereditary cerebral amyloid angiopathy, Piedmont-type mutation. Neurology Genetics, 2020, vol. 6 (2), pp. 411.
10. Kulesh A.A., Drobakha V.E., Shestakov V.V. Hemorrhagic manifestations of cerebral amyloid angiopathy – from pathogenesis to clinical significance. Nevrologiya, neyropsikhiatriya, psikhosomatika, 2018, vol. 10, no. 3, pp. 4–11 (in Russ.).
11. Van Veluw S.J., Benveniste H., Bakker E.N.T.P. et al. Is CAA a perivascular brain clearance disease? A discussion of the evidence to date and outlook for future studies. Cell. Mol. Life Sci, 2024, vol. 81 (1), p. 239.
12. Bogolepova A.N., Mkhitaryan E.A., Levin O.S. Cognitive impairment in vascular diseases of the brain. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. Spetsvypuski, 2024, vol. 124, no. 4‑2, pp. 12–16 (in Russ.).
13. Bogolepova A.N., Vasenina E.E., Gomzyakova N.A. et al. Clinical guidelines “Cognitive disorders in elderly and senile patients”. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova, 2021, vol. 121, no. 10‑3, pp. 6–137 (in Russ.).
14. Singh B., Lavezo J., Gavito-Higueroa J. et al. Updated outlook of cerebral amyloid angiopathy and inflammatory subtypes: pathophysiology, clinical manifestations, diagnosis and management. Alzheimers Disease Rep, 2022, vol. 6 (1), pp. 627–639.
15. Kulesh A.A., Gorst N.Kh., Kuzina E.V. et al. Amyloid angiitis and progressive cortical superficial siderosis as aggressive phenotypes of cerebral amyloid angiopathy: principles of rational patient management. Rossiyskiy nevrologicheskiy zhurnal, 2019, vol. 24, no. 6, pp. 29–38 (in Russ.).
16. Stanton J.E.D., Chandratheva A., Wilson D. et al. Clinical features distinguish cerebral amyloid angiopathy-associated convexity subarachnoid haemorrhage from suspected TIA. Neurology, 2020, vol. 267 (1), pp. 133–137.
17. Smith E.E., Charidimou A., Ayata S., et al. Cerebral amyloid angiopathy —related transient focal neurologic episodes. Neurology, 2021, vol. 97 (5), pp. 231–238.
18. Parfenov V.A., Bogolepova A.N., Mkhitaryan E.A. Meta-analysis of randomized controlled trials of the efficacy of Prospecta in the treatment of vascular cognitive impairment of varying severity. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova, 2024, vol. 124, no. 6, pp. 62–69 (in Russ.).
19. Fotiadis R., Reijmer Y.D., van Veluw S.J. et al. White matter atrophy in cerebral amyloid angiopathy. Neurology, 2020, vol. 95 (5), pp. 554–562.
20. Greenberg S.M., Charidimou A. Diagnosis of cerebral amyloid angiopathy: evolution of the Boston Criteria. Stroke, 2018, vol. 49 (2), pp. 491–497.
21. Pasi M., Pongpitakmetha T., Charidimou A. et al. Cerebellar microbleed distribution patterns and cerebral amyloid angiopathy: a magnetic resonance imaging and pathology-based study. Stroke, 2019, vol. 50 (7), pp. 1727–1733.
22. Charidimou A., Boulouis G., Frosch M. et al. The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study. The Lancet Neurology, 2022, vol. 21 (8), pp. 714–725.
23. Rodrigues M.A., Samarasekera N., Lerpiniere C. et al. The Edinburgh CT and genetic diagnostic criteria for lobar intracerebral haemorrhage associated with cerebral amyloid angiopathy: model development and diagnostic test accuracy study. The Lancet Neurology, 2018, vol. 17 (3), pp. 232–240.
24. Theodorou A., Tsantzali I., Kapaki E. et al. Cerebrospinal fluid biomarkers and apolipoprotein E genotype in cerebral amyloid angiopathy. A narrative review. Cereb. Circ. Cogn. Behav, 2021, vol. 2, p. 100010.
25. Charidimou A., Boulouis G. Core CSF biomarker profile in cerebral amyloid angiopathy: updated meta-analysis. Neurology, 2024, vol. 103 (7), p. 209795.
26. Charidimou A., Friedrich J.O., Greenberg S.M., Viswanathan A. Core cerebrospinal fluid biomarker profile in cerebral amyloid angiopathy: A meta analysis. Neurology, 2018, vol. 90 (9), pp. 754–762.
27. Banerjee G., Ambler G., Keshavan A. et al. Cerebrospinal fluid biomarkers in cerebral amyloid angiopathy. Alzheimers Disease, 2020, vol. 74 (4), pp. 1189–1201.
28. Kulesh A.A., Gorst N.Kh., Drobakha V.E. et al. Cerebral amyloid angiopathy associated with inflammation: a clinical observation and literature review. Permskiy meditsinskiy zhurnal, 2018, vol. XXXV, no. 6, pp. 53–60 (in Russ.).
29. Renard D., Tatu L., Collombier L. et al. Cerebral amyloid angiopathy and cerebral amyloid angiopathy-related inflammation: comparison of hemorrhagic and DWI MRI features. Alzheimers Disease, 2018, vol. 64 (4), pp. 1113–1121.
30. Zhong D., Yang T.H., Zhang Q., Wu B. Analysis of diagnosis and treatment of 6 cases of cerebral amyloid angiopathy-related inflammation. Sichuan Da Xue Xue Bao Yi Xue Ban. Chinese, 2020, vol. 51 (1), pp. 107–112.
31. Dudley A., Sweeney K., Looby S. et al. Teaching neuroimage: cerebral amyloid angiopathy–related inflammation. Neurology, 2022, vol. 99 (5), pp. 216–217.
32. Corovic A., Kelly S., Markus H.S. Cerebral amyloid angiopathy associated with inflammation: A systematic review of clinical and imaging features and outcome. Stroke, 2018, vol. 13, no. 3, pp. 257-267.
33. Powers W.J., Rabinstein A.A., Ackerson T. et al. 2018 Guidelines for the Early management of patients with acute ischemic stroke. A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 2018, vol. 49 (3), pp. 46–110.
34. Smirnova A.A., Prakhova L.N., Il’ves A.G. Immunopathogenesis and Approaches to the Development of Immunotherapy for Neurodegenerative and Cerebrovascular Diseases with Cognitive Impairment. Current State of the Problem and Prospects. Rossiyskiy nevrologicheskiy zhurnal, 2021, vol. 26, no. 5, pp. 4–15 (in Russ.).